AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Evonik Industries AG

Quarterly Report Nov 8, 2022

150_10-q_2022-11-08_14127173-bdeb-4223-a15f-b4d7d854b677.pdf

Quarterly Report

Open in Viewer

Opens in native device viewer

QUARTERLY STATEMENT

3rd quarter | First nine months 2022

A SOLID THIRD QUARTER

3rd quarter

  • In a challenging environment, organic sales growth was 10 percent due to higher selling prices, even though volumes were lower
  • Adjusted EBITDA was 5 percent lower at €615 million

1st nine months

  • Sales increased 30 percent to €14.1 billion
  • Adjusted EBITDA improved by 10 percent to €2.1 billion
  • Adjusted net income rose 26 percent to €960 million
  • Free cash flow was below the strong prior-year level at €182 million due to the price-driven rise in net working capital
  • Outlook for adjusted EBITDA 2022 confirmed: still expected to be between €2.5 billion and €2.6 billion

Key figures for the Evonik Group

3rd quarter 1st nine months
in € million 2021 2022 2021 2022
Sales 3,871 4,878 10,865 14,148
Adjusted EBITDAa 645 615 1,881 2,077
Adjusted EBITDA margin in % 16.7 12.6 17.3 14.7
Adjusted EBITb 387 342 1,121 1,270
Income before financial result and income taxes, continuing operations (EBIT) 373 326 1,060 1,202
Net income 235 214 640 824
Adjusted net income 269 253 762 960
Earnings per share in € 0.50 0.46 1.37 1.77
Adjusted earnings per share in € 0.58 0.54 1.63 2.06
Cash flow from operating activities, continuing operations 701 517 1,467 752
Cash outflows for investments in intangible assets, property, plant and equipment -177 -229 -530 -570
Free cash flowc 524 288 937 182
Net financial debt as of September 30 -2,741 -3,807
No. of employees as of September 30 32,891 33,836

a Earnings before financial result, taxes, depreciation, and amortization, after adjustments, continuing operations.

b Earnings before financial result and taxes, after adjustments, continuing operations.

c Cash flow from operating activities, continuing operations, less cash outflows for investments in intangible assets, property, plant and equipment.

Due to rounding, some figures in this report may not add up exactly to the totals stated.

CONTENTS

2
2
6
12
14
17
18
19
20
24
25
25

Business conditions and performance

1. Business performance

Business performance in Q3 2022

Given the challenging conditions, Evonik performed satisfactorily overall. The supply situation for raw materials, packaging, and logistics eased slightly, although conditions remained challenging, especially as a consequence of the war in Ukraine. The sharp hike in raw material and energy prices and general inflationary pressure had a considerable impact on supply chains, with bottlenecks in the supply of some materials that are dependent on natural gas.

Despite these difficulties, our business development was solid. Although volumes declined, the substantial rise in variable costs was more than offset by raising selling prices. Overall, adjusted EBITDA was only slightly lower than in the prior-year period.

Sales by quarter

The Evonik Group's sales increased by 26 percent to €4,878 million. Organic sales growth was 10 percent as a result of a significant improvement in selling prices, while volumes were lower. Moreover, positive currency effects and other effects contributed to the sales growth. The other effects resulted, in particular, from trading in gas and electricity by the Technology & Infrastructure division to supply external customers.

Year-on-year change in sales

in % 1st quarter 2022 2nd quarter 2022 3rd quarter 2022 1st nine months 2022
Volumes 4 -2 -7 -2
Prices 22 24 17 21
Organic sales growth 26 22 10 19
Exchange rates 4 5 7 5
Change in the scope of consolidation/other effects 4 4 9 6
Total 34 31 26 30

Adjusted EBITDA by quarter

Adjusted EBITDA decreased by 5 percent to €615 million. Earnings were lower in Nutrition & Care and Performance Materials, Smart Materials held earnings at the prior-year level, and Specialty Additives posted a considerable rise in earnings. The adjusted EBITDA margin fell from 16.7 percent in the third quarter of 2021 to 12.6 percent.

Statement of income

3rd quarter 1st nine months
in € million 2021 2022 Change in % 2021 2022 Change in %
Sales 3,871 4,878 26 10,865 14,148 30
Adjusted EBITDA 645 615 -5 1,881 2,077 10
Adjusted depreciation, amortization, and impairment
losses -258 -273 -760 -807
Adjusted EBIT 387 342 -12 1,121 1,270 13
Adjustments -14 -16 -61 -68
thereof restructuring -5 -3 -18 -26
thereof impairment losses/reversal of
impairment losses
thereof acquisition/divestment of shareholdings -5 -3 -11 -8
thereof other -4 -10 -32 -34
Income before financial result and income taxes,
continuing operations (EBIT) 373 326 -13 1,060 1,202 13
Financial result -37 -21 -98 -28
Income before income taxes, continuing
operations 336 305 -9 962 1,174 22
Income taxes -100 -90 -300 -339
Income after taxes, continuing operations 236 215 -9 662 835 26
Income after taxes, discontinued operations 4 -6
Income after taxes 240 215 -10 656 835 27
thereof income attributable to non-controlling
interests 5 1 16 11
Net income 235 214 -9 640 824 29
Earnings per share in € 0.50 0.46 1.37 1.77

The adjustments of -€16 million contained restructuring expenses in connection with the divestment of a business in the Performance Materials division. Further expenses included, among other things, the integration of acquisitions made in the past. The financial result improved to -€21 million, thanks to lower interest expense and, above all, higher interest income as a result of the higher discount rate applied to other provisions. Overall, income before income taxes, continuing operations was 9 percent lower at €305 million. Net income declined by 9 percent to €214 million.

Adjusted net income fell 6 percent to €253 million. Adjusted earnings per share dropped from €0.58 to €0.54.

3rd quarter 1st nine months
in € million 2021 2022 Change in % 2021 2022 Change in %
Adjusted EBITDA 645 615 -5 1,881 2,077 10
Adjusted depreciation, amortization, and
impairment losses -258 -273 -760 -807
Adjusted EBIT 387 342 -12 1,121 1,270 13
Adjusted financial result -37 -21 -108 -28
Amortization and impairment losses on
intangible assets 37 39 108 122
Adjusted income before income taxesa 387 360 -7 1,121 1,364 22
Adjusted income taxes -113 -106 -343 -393
Adjusted income after taxesa 274 254 -7 778 971 25
thereof adjusted income attributable to
non-controlling interests 5 1 16 11
Adjusted net incomea 269 253 -6 762 960 26
Adjusted earnings per share in €a 0.58 0.54 1.63 2.06

Reconciliation to adjusted net income

a Continuing operations.

Business performance in the first nine months of 2022

Sales grew by 30 percent to €14,148 million thanks to higher selling prices, mainly to pass on the significant increase in variable costs. Adjusted EBITDA improved 10 percent to €2,077 million. The adjusted EBITDA margin dropped to 14.7 percent, compared with 17.3 percent in the first nine months of 2021.

The adjustments of -€68 million included restructuring expenses of €26 million, principally for a new group-wide project to optimize administrative functions and the sale of a business in the Performance Materials division. Expenses for the acquisition of shareholdings related to the integration of acquisitions made in the past. The line item "Other" contains, among other things, expenses for the recognition of power derivatives, the reorganization of the superabsorbents business, and the termination of a project in Russia. In the prior-year period, the adjustments mainly comprised restructuring expenses, principally for a site in the Nutrition & Care division, and expenses in connection with the settlement of a legal dispute. The financial result improved substantially to -€28 million, thanks to lower interest expense and, above all, higher interest income as a result of the higher discount rate applied to other provisions. In addition, the reduction in the interest rate applied to interest on taxes had a positive effect. The prior-year figure contained special items of €10 million for interest income in connection with a claim to a value-added tax refund. The adjusted financial result improved from -€108 million to -€28 million. Income before income taxes, continuing operations was 22 percent higher at €1,174 million. Net income rose 29 percent to €824 million.

Adjusted net income improved by 26 percent to €960 million, while adjusted earnings per share increased from €1.63 to €2.06.

2. Performance of the divisions

Specialty Additives

Key figures

3rd quarter 1st nine months
in € million 2021 2022 Change in % 2021 2022 Change in %
External sales 934 1,113 19 2,763 3,278 19
Adjusted EBITDA 224 243 8 739 758 3
Adjusted EBITDA margin in % 24.0 21.8 26.7 23.1
Adjusted EBIT 181 194 7 609 613 1
Capital expendituresa 20 28 40 50 68 36
No. of employees as of September 30 3,704 3,785 2

a Capital expenditures for intangible assets, property, plant and equipment.

In the Specialty Additives division, sales rose 19 percent to €1,113 million in the third quarter of 2022. The sales growth resulted from considerably higher selling prices, as higher variable costs were passed on to customers, and positive currency effects. By contrast, volumes declined.

Products for the construction and coating industries and for renewable energies generated considerably higher sales as a result of successful price rises to offset higher costs. Sales of additives for polyurethane foams and consumer durables also increased, primarily on price grounds. Sales of additives for the automotive sector rose due to slightly higher volumes and improved prices.

Sales Specialty Additives

Adjusted EBITDA rose 8 percent to €243 million, driven by price adjustments, which more than offset the rise in raw material, energy, and logistics costs, and by positive currency effects. The adjusted EBITDA margin dropped back from a high level of 24.0 percent in the prior-year period to 21.8 percent.

Adjusted EBITDA Specialty Additives

In the first nine months of 2022, sales in the Specialty Additives division increased by 19 percent to €3,278 million. Since volumes were slightly lower, this was attributable to a significant rise in selling prices, mainly to pass on higher variable costs, and positive currency effects. Adjusted EBITDA improved 3 percent to €758 million. The adjusted EBITDA margin was 23.1 percent, which was below the high prior-year margin of 26.7 percent.

Nutrition & Care

Key figures

3rd quarter 1st nine months
in € million 2021 2022 Change in % 2021 2022 Change in %
External sales 931 1,062 14 2,549 3,127 23
Adjusted EBITDA 192 148 -23 517 555 7
Adjusted EBITDA margin in % 20.6 13.9 20.3 17.7
Adjusted EBIT 127 82 -35 327 357 9
Capital expendituresa 30 64 113 85 130 53
No. of employees as of September 30 5,386 5,680 5

a Capital expenditures for intangible assets, property, plant and equipment.

In the Nutrition & Care division, sales rose 14 percent to €1,062 million in the third quarter of 2022. The reasons for this were significantly higher selling prices and positive currency effects. By contrast, volumes declined, mainly because of lower demand from the animal feed industry.

Despite lower volumes, essential amino acids posted significant sales growth as a result of improved selling prices. Sales of health and care products increased, thanks to a continuing positive trend in active ingredients for cosmetic applications.

Adjusted EBITDA decreased by 23 percent to €148 million due to lower volumes and higher raw material costs. The adjusted EBITDA margin fell from 20.6 percent in the prior-year period to 13.9 percent.

Adjusted EBITDA Nutrition & Care

In the first nine months of 2022, the Nutrition & Care division's sales grew 23 percent to €3,127 million. This was principally due to the improvement in selling prices and positive currency effects. Adjusted EBITDA rose 7 percent to €555 million, mainly because of the positive price trend. The adjusted EBITDA margin declined from 20.3 percent in the prior-year period to 17.7 percent.

Smart Materials

Key figures

3rd quarter 1st nine months
in € million 2021 2022 Change in % 2021 2022 Change in %
External sales 1,002 1,259 26 2,885 3,677 27
Adjusted EBITDA 177 177 527 572 9
Adjusted EBITDA margin in % 17.7 14.1 18.3 15.6
Adjusted EBIT 111 103 -7 329 355 8
Capital expendituresa 78 69 -12 224 174 -22
No. of employees as of September 30 7,731 7,919 2

a Capital expenditures for intangible assets, property, plant and equipment.

In the Smart Materials division, sales grew 26 percent to €1,259 million in the third quarter of 2022. While volumes were basically stable, this resulted from a significant increase in selling prices and positive currency effects.

There was a substantial rise in sales of inorganic products. Demand was stable overall, and it was possible to raise selling prices significantly to recoup the rise in variable costs. Although volumes were almost unchanged, the Polymers business also registered considerably higher sales than in the prior-year period, thanks to improved selling prices.

Sales Smart Materials

Adjusted EBITDA was €177 million, in line with the prior-year level. The adjusted EBITDA margin fell from 17.7 percent in the prior-year period to 14.1 percent.

In the first nine months of 2022, sales in the Smart Materials division increased by 27 percent to €3,677 million, driven by volumes and prices. Adjusted EBITDA improved 9 percent to €572 million. The adjusted EBITDA margin dropped from 18.3 percent in the prior-year period to 15.6 percent.

Performance Materials

Key figures

3rd quarter 1st nine months
in € million 2021 2022 Change in % 2021 2022 Change in %
External sales 784 903 15 2,071 2,893 40
Adjusted EBITDA 97 74 -24 237 334 41
Adjusted EBITDA margin in % 12.4 8.2 11.4 11.5
Adjusted EBIT 63 39 -38 138 234 70
Capital expendituresa 14 16 14 32 39 22
No. of employees as of September 30 1,962 2,031 4

a Capital expenditures for intangible assets, property, plant and equipment.

Sales in the Performance Materials division climbed 15 percent to €903 million in the third quarter of 2022, with contributions coming from considerably higher prices and positive currency effects, whereas volumes decreased.

The C4 business reported lower demand, but sales were up slightly as a result of the improvement in selling prices. Sales of superabsorbents rose significantly due to higher selling prices, mainly to recoup the increase in raw material costs.

Adjusted EBITDA fell 24 percent to €74 million as a consequence of lower product margins. The adjusted EBITDA margin decreased to 8.2 percent, down from 12.4 percent in the prior-year period.

Adjusted EBITDA Performance Materials

In the first nine months of 2022, sales in the Performance Materials division grew 40 percent to €2,893 million, with volumes down slightly while prices were significantly higher. Adjusted EBITDA increased by 41 percent to €334 million, mainly due to the considerable improvement in margins in the two previous quarters. The adjusted EBITDA margin was 11.5 percent, which was around the prior-period level (11.4 percent).

Technology & Infrastructure

Key figures

3rd quarter 1st nine months
in € million 2021 2022 Change in % 2021 2022 Change in %
External sales 204 525 157 553 1,124 103
Adjusted EBITDA 27 35 30 82 65 -21
Adjusted EBITDA margin in % 13.2 6.7 14.8 5.8
Adjusted EBIT -1 6 -1 -21
Capital expendituresa 34 31 -9 84 71 -15
No. of employees as of September 30 8,154 8,308 2

a Capital expenditures for intangible assets, property, plant and equipment.

In the Technology & Infrastructure division, sales were 157 percent higher at €525 million in the third quarter of 2022, driven principally by higher natural gas and electricity prices in energy trading with external customers at our sites. Adjusted EBITDA increased by 30 percent to €35 million as a result of cost optimization. The adjusted EBITDA margin decreased from 13.2 percent to 6.7 percent.

In the first nine months of 2022, sales were up 103 percent at €1,124 million. Adjusted EBITDA declined by 21 percent to €65 million, mainly as a consequence of the increased cost of supplying energy. The adjusted EBITDA margin fell from 14.8 percent to 5.8 percent.

Financial condition

The cash flow from operating activities, continuing operations decreased by €715 million to €752 million in the first nine months of 2022. This resulted, above all, from a significant increase in net working capital as a consequence of the rise in raw material prices and higher cash outflows for bonus payments. The free cash flow was therefore €755 million below the prior-year period at €182 million.

Cash flow statement (excerpt)

1st nine months
in € million 2021 2022
Cash flow from operating activities, continuing operations 1,467 752
Cash outflows for investments in intangible assets, property, plant and equipment -530 -570
Free cash flow 937 182
Cash flow from other investing activities, continuing operations 4 121
Cash flow from financing activities, continuing operations -688 322
Change in cash and cash equivalents 253 625

The cash flow from other investing activities was €121 million and contained proceeds from the sale of current securities. The cash inflow from financing activities was €322 million and mainly related to the issuance of a new bond (€750 million) and new Schuldschein loans (€250 million), while payment of the dividend for fiscal 2021 resulted in a cash outflow of €545 million.

Net financial debt was €3,807 million, an increase of €950 million compared with December 31, 2021. This was principally due to the payment of the dividend for the previous fiscal year and additions of lease liabilities, especially due to the start-up of a gas and steam power plant in Marl (Germany).

Net financial debt

in € million Dec. 31, 2021 Sep. 30, 2022
Non-current financial liabilitiesa -3,527 -4,001
Current financial liabilitiesa -232 -1,180
Financial debt -3,759 -5,181
Cash and cash equivalents 456 1,078
Current securities 446 296
Financial assets 902 1,374
Net financial debt -2,857 -3,807

a Excluding derivatives and excluding the liabilities under rebate and bonus agreements.

The bond due in January 2023, which had a nominal value of €750 million, was reclassified from non-current to current financial liabilities. Evonik fully redeemed this bond in October 2022 by exercising a repayment right contained in the bond terms. To refinance this bond, in May 2022, Evonik Industries AG issued a green bond with a nominal value of €750 million and a tenor of 5 years and 4 months. The issue price was 99.386 percent, and the annual coupon is 2.25 percent. The proceeds from the issue will be used primarily to fund investment in our Next Generation Solutions1. To further strengthen liquidity, in August 2022, we issued Schuldschein loans with a nominal value of €250 million and a tenor of three, four, and seven years in several fixed and variable interest tranches.

In the first nine months of 2022, capital expenditures for property, plant and equipment amounted to €519 million (9M 2021: €505 million). In principle, there is a slight timing difference in cash outflows for property, plant and equipment. The expansion of capacity for isobutene derivatives at the C4 production complex in Marl (Germany) was completed. In June 2022, the groundbreaking ceremony was held for the production plant for bio-based rhamnolipids, which is currently being constructed in Slovenská L'upca (Slovakia). Investment in this plant is in the triple-digit million euro range.

1 Next Generation Solutions are products and solutions which our analysis shows have a strong sustainability profile that is above, or even well above, the market reference level.

Expected development

Our expectations for the global economic situation in 2022 have deteriorated further since the beginning of the year and are still dominated by a high degree of uncertainty. Overall, compared with 2021, we now assume lower global economic growth of 2.6 percent year-on-year in 2022 (growth assumption at the start of the year: 4.2 percent).2

The development of the global economy depends, in particular, on the further course of the war in Ukraine and its knockon effects. Persistently high or rising raw material, energy, and food prices could result in inflation becoming established at a high level, reducing disposable income and thus consumer spending.

Moreover, supply bottlenecks or a gas shortage would represent a substantial risk for the European chemical industry and the entire economy. The emergence of new coronavirus mutations and China's zero-Covid policy could lead to further disruption of global supply chains and renewed economic downturns. That would also adversely affect demand in Evonik's end-customer industries. In addition, the significant tightening of monetary policy has increased the risk of recession and a financial crisis. Last but not least, the development of the global economy could be below our expectations as a result of other geopolitical conflicts.

In view of the developments outlined above, we predict that the price of Evonik-specific raw materials will be significantly higher in 2022 than in 2021.

Our forecast is based on the following assumptions:

  • Global growth: 2.6 percent (start of 2022: 4.2 percent; May 2022: 3.3 percent; July 2022: 2.7 percent)
  • Internal raw material index: significantly higher than in the prior year (start of 2022: higher than in the prior year)

Sales and earnings

Despite the difficult global economic situation, Evonik achieved a successful operating performance in the first nine months of this year. The three growth divisions are benefiting from structural trends and continuing their positive long-term development. Equally positively, we are seeing increased demand from customers for our Next Generation Solutions, in other words, Evonik products and solutions with a superior sustainability profile. Moreover, we expect our six innovation growth fields3 to make a further contribution to growth in 2022. Our successful increases in selling prices offset the significant rise in raw material, energy, and logistics costs in the first nine months. Consequently, Evonik now anticipates that full-year sales will be around €18.5 billion (previously: between €17.0 billion and €18.0 billion; 2021: €15.0 billion). Our expectation for adjusted EBITDA is unchanged at between €2.5 billion and €2.6 billion (2021: €2,383 million). This is based on the assumption that the macroeconomic slowdown that started in the third quarter will continue and that the supply of gas will be sufficient to maintain production on the necessary scale. To be optimally prepared for a potential shortage of gas, Evonik is implementing extensive measures at its German sites to enable it to switch from natural gas to alternative energy sources.

2 Based on data from IHS Markit as of September 12, 2022.

3 See section 4. Research and development in the 2021 financial report.

We expect the development of the chemicals divisions to be as follows:

We still expect the Specialty Additives division to develop positively in 2022, driven by customer-specific solutions for more sustainable products with improved properties. Our own price rises have now offset the increases in raw material, energy, and logistics costs. Moreover, in the remainder of the year, restrictions on the availability of individual raw materials should decline further. Overall, we still anticipate that this division's earnings will be slightly above the prior-year level (2021: €920 million).

As in previous years, the Nutrition & Care division is benefiting from the continuing structural growth trend in its resilient end-markets. This division's growth will increasingly be determined by its clear focus on system solutions in the consumer goods, nutrition, and health care businesses. Following a strong first half, business development has weakened in the second half of the year. Therefore, we now expect this division's earnings to be around the prior-year level (previously: considerably higher than in the prior year; 2021: €717 million).

We still assume positive growth momentum in the Smart Materials division. This trend is driven primarily by the Inorganics business, which is benefiting from good demand for silicas and silanes for a wide range of applications as well as for catalysts. Higher raw material costs are being offset by our own price rises. In all, we expect earnings to be considerably higher than in the prior year (2021: €650 million).

In the Performance Materials division, we should benefit from a market improvement in the superabsorbents business and our long-standing customer relationships. Following the clearly positive impact of the higher naphtha price and better product margins on the performance of our C4 derivatives, especially in the first half of the year, we expect this division's earnings to be significantly higher than in the prior year (2021: €317 million).

For Technology & Infrastructure and Others4 , we assume that overall earnings will be considerably less negative than in the previous year (2021: -€221 million) despite the increase in energy costs and personnel expenses. 2021 was impacted, among other things, by insurance deductibles for weather-related damage in Europe and the USA and by power plant outages in Germany.

In 2022, the return on capital employed (ROCE) is expected to be slightly above the previous year's level (2021: 9.0 percent).

Financing and investments

We still expect cash outflows for investments in intangible assets, property, plant and equipment to be around €900 million in 2022 (2021: €865 million).

So far this year, the free cash flow has been affected by higher cash outflows from net working capital (mainly due to higher raw material costs and measures to prevent supply bottlenecks). We are continuing our efforts to reduce net working capital this year. Nevertheless, we anticipate a significant cash outflow for the full year. Moreover, as expected, the free cash flow was held back by higher bonuses for 2021. Our consistently high investment discipline has a stabilizing effect. Following the change of momentum and a clearly positive free cash flow in the third quarter, we now expect cash flow generation to gain even more strength in the fourth quarter. Consequently, for the free cash flow 2022, we assume a cash conversion rate5 of around 30 percent (2021: 40 percent). With adjusted EBITDA expected to be between €2.5 billion and €2.6 billion, the absolute free cash flow is therefore likely to be below the prior-year level (2021: €950 million).

4 Enabling functions, other activities, consolidation.

5 Ratio of free cash flow to adjusted EBITDA.

Forecast for 2022

Forecast performance indicators 2021 Forecast for 2022a Revised forecast
as of August 2022b
Current
forecast for 2022
Group sales €15.0 billion Between €15.5 billion
and €16.5 billion
Between €17.0 billion
and €18.0 billion
Around €18.5 billion
Adjusted EBITDA €2.4 billion Between €2.5 billion
and €2.6 billion
Between €2.5 billion
and €2.6 billion
Between €2.5 billion
and €2.6 billion
ROCE 9.0% Slightly above the
prior-year level
Slightly above the
prior-year level
Slightly above the
prior-year level
Cash outflows for investments in intangible assets,
property, plant and equipment
€865 million Around €900 million Around €900 million Around €900 million
Free cash flow: cash conversion ratec 40% Around 40% Around 30% Around 30%

a As in the financial report 2021.

b As in the half-year financial report 2022.

c Ratio of free cash flow to adjusted EBITDA.

Income statement

3rd quarter 1st nine months
in € million 2021 2022 2021 2022
Sales 3,871 4,878 10,865 14,148
Cost of sales -2,807 -3,784 -7,741 -10,619
Gross profit on sales 1,064 1,094 3,124 3,529
Selling expenses -436 -540 -1,244 -1,544
Research and development expenses -118 -115 -333 -340
General administrative expenses -148 -129 -406 -414
Other operating income 43 71 143 175
Other operating expense -34 -56 -230 -212
Result from investments recognized at equity 2 1 6 8
Income before financial result and income taxes, continuing operations (EBIT) 373 326 1,060 1,202
Interest income 5 24 25 75
Interest expense -34 -32 -101 -80
Other financial income/expense -8 -13 -22 -23
Financial result -37 -21 -98 -28
Income before income taxes, continuing operations 336 305 962 1,174
Income taxes -100 -90 -300 -339
Income after taxes, continuing operations 236 215 662 835
Income after taxes, discontinued operations 4 -6
Income after taxes 240 215 656 835
thereof attributable to non-controlling interests 5 1 16 11
thereof attributable to shareholders of Evonik Industries AG (net income) 235 214 640 824
Earnings per share in € (basic and diluted) 0.50 0.46 1.37 1.77
thereof continuing operations 0.49 0.46 1.38 1.77
thereof discontinued operations 0.01 0.00 -0.01 0.00

Prior-year figures restated.

Balance sheet

in € million Dec. 31, 2021 Sep. 30, 2022
Goodwill 4,785 5,095
Other intangible assets 1,260 1,237
Property, plant and equipment 6,963 7,239
Right-of-use assets 608 896
Investments recognized at equity 81 83
Other financial assets 581 403
Deferred taxes 1,755 1,091
Other income tax assets 16 18
Other non-financial assets 125 79
Non-current assets 16,174 16,141
Inventories 2,548 3,450
Trade accounts receivable 1,954 2,327
Other financial assets 571 441
Other income tax assets 199 151
Other non-financial assets 382 595
Cash and cash equivalents 456 1,078
6,110 8,042
Assets held for sale 98
Current assets 6,110 8,140
Total assets 22,284 24,281
Issued capital 466 466
Capital reserve 1,168 1,168
Retained earnings 7,767 9,596
Other equity components -112 483
Equity attributable to shareholders of Evonik Industries AG 9,289 11,713
Non-controlling interests 83 84
Equity 9,372 11,797
Provisions for pensions and other post-employment benefits 3,766 1,655
Other provisions 657 628
Other financial liabilities 3,531 4,043
Deferred taxes 628 678
Other income tax liabilities 195 209
Other non-financial liabilities 143 164
Non-current liabilities 8,920 7,377
Other provisions 892 739
Trade accounts payable 2,022 2,013
Other financial liabilities 477 1,521
Other income tax liabilities 211 225
Other non-financial liabilities 390 596
3,992 5,094
Liabilities associated with assets held for sale 13
Current liabilities 3,992 5,107
Total equity and liabilities 22,284 24,281

Cash flow statement

3rd quarter 1st nine months
in € million 2021 2022 2021 2022
Income before financial result and income taxes, continuing operations 373 326 1,060 1,202
Depreciation, amortization, impairment losses/reversal of impairment losses on
non-current assets 260 275 761 813
Result from investments recognized at equity -2 -2 -6 -8
Gains/losses on the disposal of non-current assets 21 3
Change in inventories -181 -123 -500 -737
Change in trade accounts receivable -62 192 -382 -270
Change in trade accounts payable 84 -184 324 -19
Change in provisions for pensions and other post-employment benefits 10 -5 52 25
Change in other provisions 163 85 107 -138
Change in miscellaneous assets/liabilities 40 12 90 54
Cash inflows from dividends 1 18 15
Cash outflows for income taxes -57 -78 -194 -288
Cash inflows from income taxes 72 19 116 100
Cash flow from operating activities, continuing operations 701 517 1,467 752
Cash outflows for investments in intangible assets, property, plant and equipment -177 -229 -530 -570
Cash outflows to obtain control of businesses -37 -39
Cash outflows relating to the loss of control over businesses -145
Cash outflows for investments in other shareholdings -6 -6 -10 -18
Cash inflows from divestments of intangible assets, property, plant and equipment 8 3
Cash inflows relating to the loss of control over businesses 4 4
Cash inflows from divestment of other shareholdings 1 2
Cash inflows/outflows relating to securities, deposits, and loans -99 38 178 120
Cash inflows from interest 3 5 10 12
Cash flow from investing activities, continuing operations -315 -188 -526 -449
Cash outflows for dividends to shareholders of Evonik Industries AG -536 -545
Cash outflows for dividends to non-controlling interests -1 -20 -11
Cash outflows due to changes in ownership interests in subsidiaries -5 -5
Cash outflows for the purchase of treasury shares -15 -16
Cash inflows from the sale of treasury shares 12 12
Cash inflows from the addition of financial liabilities 533 426 617 1,508
Cash outflows for repayment of financial liabilities -573 -331 -758 -472
Cash inflows/outflows in connection with financial transactions -5 -39 84 -103
Cash outflows for interest -38 -23 -72 -46
Cash flow from financing activities, continuing operations -83 27 -688 322
Change in cash and cash equivalents 303 356 253 625
Cash and cash equivalents as of July 1/January 1 520 731 563 456
Change in cash and cash equivalents 303 356 253 625
Changes in exchange rates and other changes in cash and cash equivalents -2 4 5 10
Cash and cash equivalents as of September 30 821 1,091 821 1,091
Cash and cash equivalents included in assets held for sale 13 13
Cash and cash equivalents as on the balance sheet as of September 30 821 1,078 821 1,078

Segment report

Segment report by operating segments—3rd quarter

Specialty Additives Nutrition & Care Smart Materials
in € million 2021 2022 2021 2022 2021 2022
External sales 934 1,113 931 1,062 1,002 1,259
Internal sales 2 2 -1 3 21 26
Total sales 936 1,115 930 1,065 1,023 1,285
Adjusted EBITDA 224 243 192 148 177 177
Adjusted EBITDA margin in % 24.0 21.8 20.6 13.9 17.7 14.1
Adjusted EBIT 181 194 127 82 111 103
Capital expendituresa 20 28 30 64 78 69
Financial investments 49 1 1

a For intangible assets, property, plant and equipment.

Segment report by regions—3rd quarter

Europe, Middle East & Africa North America
in € million 2021 2022 2021 2022
External salesa 1,891 2,520 911 1,193
Capital expenditures 139 149 23 53

a External sales Europe, Middle East & Africa: thereof Germany €715 million (Q3 2021: €638 million).

Performance Materials
Technology & Infrastructure
Enabling functions, other activities,
consolidation
Total Group
(continuing operations)
2021 2022 2021 2022 2021 2022 2021 2022
784 903 204 525 16 16 3,871 4,878
40 54 365 443 -427 -528
824 957 569 968 -411 -512 3,871 4,878
97 74 27 35 -72 -62 645 615
12.4 8.2 13.2 6.7 16.7 12.6
63 39 -1 6 -94 -82 387 342
14 16 34 31 6 13 182 221
3 10 53 11
Central & South America Asia-Pacific Total Group
(continuing operations)
2021 2022 2021 2022 2021 2022
186 260 883 905 3,871 4,878
4 2 16 17 182 221

Segment report by operating segments—1st nine months

Specialty Additives Nutrition & Care Smart Materials
in € million 2021 2022 2021 2022 2021 2022
External sales 2,763 3,278 2,549 3,127 2,885 3,677
Internal sales 7 6 5 8 46 68
Total sales 2,770 3,284 2,554 3,135 2,931 3,745
Adjusted EBITDA 739 758 517 555 527 572
Adjusted EBITDA margin in % 26.7 23.1 20.3 17.7 18.3 15.6
Adjusted EBIT 609 613 327 357 329 355
Capital expendituresa 50 68 85 130 224 174
Financial investments 49 1 5 12
No. of employees as of September 30 3,704 3,785 5,386 5,680 7,731 7,919

a For intangible assets, property, plant and equipment.

Segment report by regions—1st nine months

Europe, Middle East & Africa North America
in € million 2021 2022 2021 2022
External salesa 5,336 7,260 2,538 3,333
Non-current assets in accordance with IFRS 8 as of September 30 7,329 7,717 4,182 4,853
Capital expenditures 406 361 61 114
No. of employees as of September 30 22,366 22,876 4,795 5,011

Prior-year figures restated.

a External sales Europe, Middle East & Africa: thereof Germany €2,214 million (9M 2021: €1,784 million).

Performance Materials Technology & Infrastructure Enabling functions, other activities,
consolidation
Total Group
(continuing operations)
2021 2022 2021 2022 2021 2022 2021 2022
2,071 2,893 553 1,124 44 49 10,865 14,148
96 166 1,064 1,297 -1,218 -1,545
2,167 3,059 1,617 2,421 -1,174 -1,496 10,865 14,148
237 334 82 65 -221 -207 1,881 2,077
11.4 11.5 14.8 5.8 17.3 14.7
138 234 -1 -21 -281 -268 1,121 1,270
32 39 84 71 30 37 505 519
1 7 18 61 32
1,962 2,031 8,154 8,308 5,954 6,113 32,891 33,836
Central & South America Asia-Pacific Total Group
(continuing operations)
2021 2022 2021 2022 2021 2022
490 741 2,501 2,814 10,865 14,148
164 173 1,877 1,885 13,552 14,628
6 5 32 39 505 519
699 728 5,031 5,221 32,891 33,836

Appendix

Restatement of prior-year figures

Restatement in the income statement

The presentation of the adjustments was altered as of December 31, 2021. Irrespective of their classification as adjustments, they are now allocated to the relevant function costs. The prior-year figures have been restated.

Impact on the income statement

2021
in € million 3rd quarter 1st nine
months
Sales
Cost of sales -5 -21
Gross profit on sales -5 -21
Selling expenses -2
Research and development expenses
General administrative expenses -3 -5
Other operating income -3
Other operating expense 8 31
Result from investments recognized at equity
Income before financial result and income taxes, continuing operations (EBIT)

Restatement in the segment report

The definition of non-current assets in accordance with IFRS 8 Operating Segments was adjusted as of December 31, 2021. Alongside goodwill, other intangible assets, property, plant and equipment, and right-of-use assets, non-current assets in accordance with IFRS 8 now also include investments recognized at equity and non-current other non-financial assets. The prior-year figures have been restated.

Changes in the Evonik Group

Assets held for sale and discontinued operations

The TAA derivatives business of the Specialty Additives division is presented as held for sale on the balance sheet as of September 30, 2022. TAA derivatives are essential precursors for the production of light stabilizers. The business includes property, plant and equipment of €35 million and goodwill of €22 million.

Financial calendar

Financial calendar 2023

Event Date
Report on Q4 2022 and FY 2022 March 2, 2023
Interim report Q1 2023 May 9, 2023
Annual shareholders' meeting 2023 May 31, 2023
Interim report Q2 2023 August 4, 2023
Interim report Q3 2023 November 7, 2023

Credits

Published by

Evonik Industries AG Rellinghauser Strasse 1–11 45128 Essen, Germany www.evonik.com

Contact Communications

Phone +49 201 177-3315 [email protected]

Investor Relations

Phone +49 201 177-3146 [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.